In the interesting Landmark Paper Shows Pfizer/BioNTech’s mRNA Tech is Error-Prone investigative journalist Sonia Elijah brings attention to a significant study from Cambridge University. The study by Mulroney et al. from Cambridge University, together with researchers from the Universities of Kent, Oxford and Liverpool, shows that the mRNA technology, the one used in the mRNA injections, is error-prone. This research indicates that the mRNA shots may inadvertently produce “off-target” proteins, leading to unintended immune responses in vaccinated individuals. This may mean the widespread distribution of the Pfizer/BioNTech mRNA COVID-19 vaccines may constitute a bigger risk than expected.
The Mechanism Behind Off-Target Proteins
The study results reveal that one-third of the 21 participants experienced immune responses to unintended proteins generated by the vaccine. The researchers pinpointed the cause of these unintended effects to a specific modified nucleoside used in the vaccine—N1-Methylpseudouridine (1-methylΨ). This synthetic component is integral to enhancing mRNA stability but has been shown to trigger ribosomal frameshifting during protein synthesis. This process can lead to the production of proteins that differ from what was originally intended. During translation, ribosomes—the cellular machinery responsible for decoding mRNA—can misread sequences due to 1-methylΨ, resulting in altered amino acid chains. This deviation can produce proteins with unexpected functions or structures.
Implications for Future mRNA Therapies
These revelations come on the heels of the so-called “Blotgate” scandal earlier this year, where allegations surfaced regarding BioNTech’s Western Blot tests used to validate their product’s integrity. An investigative report suggested possible fabrication in test results, raising further questions about vaccine safety. Sonia Elijah writes in her article about “Blotgate” that “An anonymous source provided evidence revealing how BioNTech’s automated (computerised) Western Blots had appeared to be ‘copied and pasted’ across four different batches of the vaccine, transfected at six different concentrations.”
Regulatory Response and Public Health Implications
The discovery that proteins like this may arise post-vaccination necessitates thorough risk assessments by regulatory bodies regarding past or potential harms. Critics of the study mean it reflects a broader failure in regulatory oversight regarding vaccine safety and experts are calling for transparency from UK regulators and international agencies like the FDA regarding their awareness of these findings and what measures are being taken to address them. The necessity for ongoing research into mRNA technology and its implications for public health is absolutely paramount.
Read more in Sonia Elijah’s article at Trial Site News and the study itself
